Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

EP: 1.Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

EP: 2.ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

EP: 3.cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

EP: 4.Examining 3-Year Update Data from the CASPIAN Trial

EP: 5.Predictors of Immunotherapy Response in Limited and Extensive SCLC

EP: 6.Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

EP: 7.Examining the use of PD-L1 and tTMB in the CASPIAN Trial

EP: 8.Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

Now Viewing

EP: 9.Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

EP: 10.DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

EP: 11.Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

EP: 12.Examining Key Data from DAREON-8

EP: 13.Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

Video content above is prompted by the following questions:

• After frontline therapy in limited-stage small cell lung cancer (LS-SCLC), how do you determine the appropriate second-line and subsequent therapy?
  • What patient-specific factors do you consider?
  • Other than clinical trial enrollment, what would you consider for second-line treatment?
  • Please briefly describe the SWOG umbrella protocol for ES-SCLC
• Can we personalize treatment by identifying molecular subtypes that may be more responsive to certain therapies than others?
• Please provide your insights on the potential for improved survival benefits with chemoimmunotherapy and consolidative thoracic radiotherapy in patients with ES-SCLC.
  • What additional research should be conducted to further validate the use of CIT and cTRT in this patient population?
• Please briefly comment on key updates in SCLC recently presented at ASCO 2024 and discuss how these findings may impact the overall treatment landscape.